CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
AL Beitelshees, CD Thomas, PE Empey… - Journal of the …, 2022 - Am Heart Assoc
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with …
CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with …
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
AL Beitelshees, CD Thomas, PE Empey… - Journal of the …, 2022 - europepmc.org
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
[HTML][HTML] CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
AL Beitelshees, CD Thomas, PE Empey… - Journal of the …, 2022 - ncbi.nlm.nih.gov
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with …
CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with …
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
AL Beitelshees, CD Thomas… - Journal of the …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
[PDF][PDF] CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
AL Beitelshees, CD Thomas, PE Empey, GA Stouffer… - 2022 - scholarworks.iupui.edu
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
AL Beitelshees, CD Thomas, PE Empey, GA Stouffer… - 2022 - scholarworks.iupui.edu
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
AL Beitelshees, CD Thomas, PE Empey… - Journal of the …, 2022 - europepmc.org
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
AL Beitelshees, CD Thomas… - Journal of the …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Studies have demonstrated increased risk of major atherothrombotic events in
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …
CYP2C19 loss-of-function (LOF) variant carriers versus non-carriers treated with clopidogrel …